Q-State Biosciences and UCB Form Research Collaboration to Develop Novel Therapeutics for Genetic Subtypes of Epilepsy

- Discovery Program will be the first application of Q-State stem cell and Optopatch platforms for drug discovery

CAMBRIDGE, MA. and Brussels, Belgium. April 4, 2017. Q-State Biosciences (“Q-State”) and UCB today announced that they have entered into a multi-year therapeutics discovery collaboration. The joint program will employ a precision-medicine approach to the development of novel therapeutics for epilepsy, and particularly genetically defined subtypes of childhood epilepsy that present with substantial morbidity, taking advantage of Q-State’s proprietary optogenetics platform.

Financial terms are not being disclosed, nor are the genetic targets that are the subject of the research. The program includes research support, as well as prospective preclinical and clinical milestones and royalties.

The impact of genetic changes on neuronal function is not well understood, and targeted therapies for epilepsy patients suffering from such monogenic diseases are not currently available. The collaboration calls for Q-State to build disease models using stem cell-derived neurons from epilepsy patients that can be employed with Q-State’s proprietary Optopatch technology. Optopatch permits the fine interrogation of neuronal networks by optical stimulation and recording and identifies the deficits in neuronal activity caused by genetic mutations. By coupling this platform with neuronal cell lines derived from epilepsy patients, the collaboration aims to characterize neuronal and network dysfunction with unparalleled precision. It also seeks to identify new therapies addressing the specific deficit unique to each epilepsy.

This alliance involves the application of a combined UCB/Q-State small molecule chemical library and collaborative medicinal chemistry effort. The goal is to identify and bring to clinical development therapeutics that can efficiently treat seizures in patients with genetic mutations.

“We are excited at the opportunity to make a real difference for such a devastating set of disorders, and to be doing it with the global leader in epilepsy therapeutics” said Jonathan Fleming, Q-State’s President and CEO, “Genetically defined indications such as these represent an ideal target for the Q-State approach, and we have high hopes that the combined efforts of our two companies will yield
new treatments. These patients and their families are in desperate need of help, and innovative approaches based directly on these patients' neurons are likely to be the best way to get it to them."

“This collaboration is core to our genetics strategy at UCB which is to move from high unmet needs of specific patient sub-populations to providing transformational medicines to these subpopulations using innovative science”, said Ismail Kola, UCB’s Chief Scientific Officer. “By coupling our epilepsy expertise with Q-State’s scientific excellence and technology platforms, we hope to accelerate the search of a new treatment for this severe disease.”

For further information UCB

Corporate Communications
France Nivelle,
Global Communications, UCB
T +32.2.559.9178, france.nivelle@ucb.com
Laurent Schots,
Media Relations, UCB T+32.2.559.92.64,
Laurent.schots@ucb.com

Investor Relations
Antje Witte,
Investor Relations, UCB
T +32.2.559.94.14, antje.witte@ucb.com
Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588,
isabelle.ghellynck@ucb.com

About Q-State Biosciences:
Our mission is to develop precision therapeutics and diagnostics for genetically defined disorders of the nervous system through the interrogation of human cellular models of disease using advanced measurement technologies.

The company represents the fusion of stem cell technologies from Prof. Kevin Eggan, optogenetics technologies from Prof. Adam Cohen, both of Harvard University, and the MANTRA™ electric-field stimulation screening system recently acquired from Galenea Corp.

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With more than 7500 people in approximately 40 countries, the company generated revenue of €4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Forward looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with
research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.